Mauna Kea wins 510(k) for new urinary tract probes; Synergetics improves finances through more contract manufacturing;

@FierceMedDev: Quotient, a UK diagnostics outfit, filed plans for a $75M IPO. Via Renaissance Capital. Brief | Follow @FierceMedDev

@MarkHFierce: The European Patent Office tossed out an Edwards heart valve patent--a big victory for rival Medtronic. More | Follow @MarkHFierce

@MichaelGFierce: Study: In two-drug, HIV-preventing vaginal ring, only one drug does the job. Piece | Follow @MichaelGFierce

@EmilyWFierce: Stapler-sized device could identify disease biomarkers and insulin levels, all in one read. Story via RTT News | Follow @EmilyWFierce

@GalenMoore: Last year's M&A darling, Biomet files for an IPO. It's said to be looking for a $1B raise. News | Follow @GalenMoore

> France's Mauna Kea Technologies gained a 510(k) clearance to cover the use of its Cellvizio technology to probe the urethra, bladder and ureter by way of an endoscope or related accessories. Item 

> Medical device manufacturer Synergetics ($SURG)  boosted net sales and reduced net losses in its recently-concluded second quarter, thanks to strong gains in its contract manufacturing business. Item

> The Gores Group and Technology4Medicine in metro-Los Angeles have snatched up Fotona, a Slovenia operation that manufactures medical lasers. Story

> The BioMaryland Center handed out $1.5 million in awards to Johns Hopkins and 7 biotech companies for projects including the development of a device that would lessen some risks involved with cardiac ablation. Item

> The Medical Imaging and Technology Alliance is pursuing a new campaign to educate policymakers about how medical imaging improves healthcare and can lower costs. Item

Biotech News

@FierceBiotech: After 2 years trailing Boston, San Francisco rules our list of the top 15 cities for biotech VC. Report | Follow @FierceBiotech

@JohnCFierce: And continuing to run strong from Wednesday, which is unusual--FDA rejects Eli Lilly's SGLT2 diabetes drug empagliflozin. Story | Follow @JohnCFierce

@DamianFierce: New Link's cancer vaccine brings hopeful investors back down to earth. More | Follow @DamianFierce

@EmilyMFierce: Stem cell therapy developed by International Stem Cell Corp. improves Parkinsons symptoms in monkeys. Story | Follow @EmilyMFierce

> GlaxoSmithKline's FDA batting average tops the industry; Lilly, not so much. Article

> A Phase III win puts Incyte's cancer drug in line for blockbuster status. Piece

Pharma News

@FiercePharma: And the best-read special report, our newest: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: ICYMI: It's trial by fire for Zogenix, as painkiller Zohydro's launch meets public furor. News | Follow @TracyStaton

@EricPFierce: Novartis has more skin in the dermatology game with EU approval of Xolair to treat chronic hives. Story | Follow @EricPFierce

@CarlyHFierce: Working on a new report... looks like it's time to add "write extensive Advair pieces off the top of my head" to my list of party tricks. | Follow @CarlyHFierce

> Pfizer recalls 104,000 bottles of antidepressant Effexor XR. Story

> Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.